Neuronal ceroid lipofuscinoses therapeutic strategies: Past, present and future

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 10, 2006, Pages 945-953

  Hobert, Judith A ^a   Dawson, Glyn ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemical chaperone therapy; Enzyme therapy; Gene therapy; Neuronal ceroid lipofuscinoses; Stem cell therapy

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BUTYLCRESOL; CARBAMAZEPINE; CARNITINE; CYSTAFOS; DIAZEPAM; ENZYME; GENTAMICIN; GLUCOSYLCERAMIDASE; HALOPERIDOL; LITHIUM; MERCAPTAMINE; METHIONINE; OMEGA 3 FATTY ACID; PHENYTOIN; PYRIDOXINE; RIBOFLAVIN; SODIUM SELENITE; TRIPEPTIDYL PEPTIDASE I; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; ENZYME REPLACEMENT; GAUCHER DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; NEURAL STEM CELL; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD; VIRAL GENE THERAPY;

ANIMALS; CLINICAL TRIALS; DIETARY SUPPLEMENTS; GENE THERAPY; HUMANS; LYSOSOMES; MICE; MOLECULAR CHAPERONES; NEURONAL CEROID-LIPOFUSCINOSES; STEM CELL TRANSPLANTATION;

EID: 33751019158     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.08.004     Document Type: Review

References (63)

1. Siintola E., Partanen S., Stromme P., Haapenen A., Haltia M., Maehlen J., Lehesjoki A., and Tyynela J. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129 (2006) 1438-1445
2. Burneo J.G., Arnold T., Palmer C.A., Kuzniecky R.I., Oh S.J., and Faught E. Adult-onset neuronal ceroid lipofuscinosis (Kufs disease) with autosomal dominant inheritance in Alabama. Epilepsia 44 6 (2003) 841-846
3. Schulz A., Dhar S., Rylova S., Dbaibo G., Alroy J., Hagel C., Artacho I., Kohlschutter A., Lin S., and Boustany R.M. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Annals of Neurology 56 3 (2004) 342-350
4. Schulz A. The CLN9 protein, a regulator of dihydroceramide synthase. Journal of Biological Chemistry 281 5 (2006) 2784-2794
5. Tang. Murine cathepsin f deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Molecular and Cellular Biology 26 6 (2006) 2309-2316
6. Yoshikawa M., Uchida S., Ezaki J., Rai T., Hayama A., Kobayashi K., Kida Y., Noda M., Koike M., Uchiyama Y., Marumo F., Kominami E., and Sasaki S. CLC-3 deficiency leads to phenotypes similar to human neuronal ceroid lipofuscinosis. Genes to Cells 7 6 (2002) 597-605
7. Kasper D., et al. Loss of the chloride channel CLC-7 leads to lysosomal storage disease and neurodegeneration. The EMBO Journal 24 (2005) 1079-1091
8. Hofmann S.L., Atashband A., Cho S.K., Das A.K., Gupta P., and Lu J.Y. Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2). Current Molecular Medicine 2 5 (2002) 423-437
9. Ezaki J., Takeda-Ezaki M., and Kominami E. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase. Journal of Biochemistry 128 3 (2000) 509-516
10. Philippart M. Diagnosis and treatment of typical and atypical forms of lipopigment storage disorders. American Journal of Medical Genetics - Supplement 5 (1988) 291-298
11. Philippart M., Messa C., and Chugani H.T. Spielmeyer-Vogt (Batten, Spielmeyer-Sjogren) disease. Distinctive patterns of cerebral glucose utilization. Brain 117 Pt 5 (1994) 1085-1092
12. Wisniewski K.E. Neuronal ceroid-lipofuscinoses. Gene Reviews (2005). http:www.genetests.org www.genetests.org (online)
13. Boustany R.-M. Seizures, depression and dementia in teenagers with batten disease. Journal of Inherited Metabolic Disease 16 (1993) 252-255
14. Armstrong D., Dimmitt S., and VanWormer D.E. Studies in batten disease. I. Peroxidase deficiency in granulocytes. Archives of Neurology 30 2 (1974) 144-152
15. Armstrong D. Peroxidase activity in human and canine ceroid-lipofuscinosis, with special emphasis on the eye. In: Armstrong D., Koppang N., and Rider J.A. (Eds). Ceroid-Lipofuscinosis (Batten's Disease) (1982), Elsevier Biomedical Press, Amsterdam 247-270
16. Westermarck T., and Sandholm M. Decreased erythrocyte glutathione peroxidase activity in neuronal lipofuscinosis (NCL)-corrected with selenium supplementation. Acta Pharmacologica et Toxicologica 40 1 (1977) 70-74
17. Naidu S., Maumanee I., Olson J., Borel J., and Moser H. Selenium treatment in neuronal ceroid-lipofuscinosis. American Journal of Medical Genetics-Supplement 5 (1988) 283-289
18. Santavuori P., and Moren R. Experience of antioxidant treatment in neuronal ceroid-lipofuscinosis of Spielmeyer-Sjogren type. Neuropadiatrie 8 4 (1977) 333-344
19. Santavuori P., Heiskala H., Autti T., Johansson E., and Westermarck T. Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment. Advances in Experimental Medicine and Biology 266 (1989) 273-282
20. Dawson G. In: Rider W.Z.a.J. (Ed). The Dissection of a Degenerative Disease (1975), American Elsevier, New York 266
21. Jensen G.E., Clausen J., Melchior J.C., and Konat G. Clinical, social and biochemical studies on Batten's syndrome, alias Spielmeyer-Vogot or Stengel's Syndrome. European Neurology 15 4 (1977) 203-211
22. Tsan M.F., Gale A.N., Murphy E.A., and McIntyre P.A. Neuronal ceroid-lipofuscinosis. Studies of granulocyte enzyme activities. Journal of the Neurological Sciences 36 1 (1978) 13-24
23. Bennett M.J., Hosking G.P., Gayton R., Thompson G., Galloway J.H., and Cartwright I.J. Therapeutic modification of membrane lipid abnormalities in juvenile neuronal ceroid-lipofuscinosis (Batten disease). American Journal of Medical Genetics-Supplement 5 (1988) 275-281
24. Bennett M.J., Gayton A.R., Rittey C.D., and Hosking G.P. Juvenile neuronal ceroid-lipofuscinosis: developmental progress after supplementation with polyunsaturated fatty acids. Developmental Medicine and Child Neurology 36 7 (1994) 630-638
25. Katz M.L. Decreased plasma carnitine and trimethyl-l-lysine levels associated with lysosomal accumulation of a trimethyl-l-lysine containing protein in Batten disease. Biochimica et Biophysica Acta 1317 3 (1996) 192-198
26. Dawson G., Kilkus J., Siakotos A.N., and Singh I. Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease. Molecular and Chemical Neuropathology 29 2-3 (1996) 227-235
27. Katz M.L., Rice L.M., and Gao C.L. Dietary carnitine supplements slow disease progression in a putative mouse model for hereditary ceroid-lipofuscinosis. Journal of Neuroscience Research 50 1 (1997) 123-132
28. Siakotos A.N., Hutchins G.D., Farlow M.R., and Katz M.L. Assessment of dietary therapies in a canine model of Batten disease. European Journal of Paediatric Neurology 5 Suppl. A (2001) 151-156
29. Moser H., Raymond G.V., and Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 294 24 (2005) 3131-3134
30. Moser H., Raymond G.V., Lu S.E., Muenz L.R., Moser A.B., Xu J., Jones R.O., Loes D.J., Melhem E.R., Dubey P., Bezman L., Brereton N.H., and Odone A. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Archives of Neurology 62 7 (2005) 1073-1080
31. Cohen F.E., and Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 426 18 (2003) 905-909
32. Okumiya T., Ishii S., Takenaka T., Kase R., Kamei S., Sakuraba H., and Suzuki Y. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochemical and Biophysical Research Communications 214 3 (1995) 1219-1224
33. Asano N. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. European Journal of Biochemistry 267 (2000) 4179-4186
34. Frustaci A., Chimenti C., Ricci R., Natale L., Russo M.A., Pieroni M., Eng C.M., and Desnick R.J. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. New England Journal of Medicine 345 1 (2001) 25-32
35. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., and Kelly J.W. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America 99 24 (2002) 15428-15433
36. Matsuda J., Suzuki O., Oshima A., Yamamoto Y., Noguchi A., Takimoto K., Itoh M., Matsuzaki Y., Yasuda Y., Ogawa S., Sakata Y., Nanba E., Higaki K., Ogawa Y., Tominaga L., Ohno K., Iwasaki H., Watanabe H., Brady R.O., and Suzuki Y. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proceedings of the National Academy of Sciences of the United States of America 100 26 (2003) 15912-15917
37. Dawson G., Dawson S.A., Marinzi C., and Dawson P.E. Anti-tumor promoting effects of palmitoyl: protein thioesterase inhibitors against a human neurotumor cell line. Cancer Letters 187 1-2 (2002) 163-168
38. Zhang Z., Butler J.D., Levin S.W., Wisniewski K.E., Brooks S.S., and Mukherjee A.B. Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood. Nature Medicine 7 4 (2001) 478-484
39. Lu J.Y., and Hofmann S.L. Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis. Journal of Inherited Metabolic Disease 29 (2006) 119-126
40. Sleat D.E., Sohar I., Gin R.M., and Lobel P. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. European Journal of Paediatric Neurology 5 Suppl. A (2001) 57-62
41. Vellodi A. Lysosomal storage disorders. British Journal of Haematology 128 4 (2005) 413-431
42. Schiffmann R., Heyes M.P., Aerts J.M., Dambrosia J.M., Patterson M.C., DeGraba T., Parker C.C., Zirzow G.C., Oliver K., Tedeschi G., Brady R.O., and Barton N.W. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Annals of Neurology 42 4 (1997) 613-621
43. Rice E.O., Mifflin T.E., Sakallah S., Lee R.E., Sansieri C.A., and Barranger J.A. Gaucher disease: studies of phenotype, molecular diagnosis and treatment. Clinical Genetics 49 3 (1996) 111-118
44. Lin L., and Lobel P. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochemical Journal 357 Pt 1 (2001) 49-55
45. Lonser R.R., Walbridge S., Murray G.J., Aizenberg M.R., Vortmeyer A.O., Aerts J.M., Brady R.O., and Oldfield E.H. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Annals of Neurology 57 4 (2005) 542-548
46. Hopwood J.J., Vellodi A., Scott H.S., Morris C.P., Litjens T., Clements P.R., Brooks D.A., Cooper A., and Wraith J.E. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. Journal of Inherited Metabolic Disease 16 6 (1993) 1024-1033
47. Norflus F., Tifft C.J., McDonald M.P., Goldstein G., Crawley J.N., Hoffmann A., Sandhoff K., Suzuki K., and Proia R.L. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. Journal of Clinical Investigation 101 9 (1998) 1881-1888
48. Unger E.R., Sung J.H., Manivel J.C., Chenggis M.L., Blazar B.R., and Krivit W. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. Journal of Neuropathology and Experimental Neurology 52 5 (1993) 460-470
49. Deeg H.J., Shulman H.M., Albrechtsen D., Graham T.C., Storb R., and Koppang N. Batten's disease: failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model. Clinical Genetics 37 4 (1990) 264-270
50. Lake B.D., Steward C.G., Oakhill A., Wilson J., and Perham T.G. Bone marrow transplantation in late infantile Batten disease and juvenile Batten disease. Neuropediatrics 28 1 (1997) 80-81
51. Lonnqvist T., Vanhanen S.L., Vettenranta K., Autti T., Rapola J., Santavuori P., and Saarinen-Pihkala U.M. Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis. Neurology 57 (2001) 1411-1416
52. Yuza Y., Yokoi K., Sakurai K., Ariga M., Yanagisawa T., Ohashi T., Hoshi Y., and Eto Y. Allogenic bone marrow transplantation for late-infantile neuronal ceroid lipofuscinosis. Pediatrics International 47 (2005) 681-683
53. Young P.P., Fantz C.R., and Sands M.S. VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiency. Experimental Neurology 188 1 (2004) 104-114
54. Escolar M.L., Poe M.D., Provenzale J.M., Richards K.C., Allison J., Wood S., Wenger D.A., Pietryga D., Wall D., Champagne M., Morse R., Krivit W., and Kurtzberg J. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. [see comment]. New England Journal of Medicine 352 20 (2005) 2069-2081
55. Brooks A.I., Stein C.S., Hughes S.M., Heth J., McCray Jr. P.M., Sauter S.L., Johnston J.C., Cory-Slechta D.A., Federoff H.J., and Davidson B.L. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. [see comment]. Proceedings of the National Academy of Sciences of the United States of America 99 9 (2002) 6216-6221
56. Griffey M., Bible E., Vogler C., Levy B., Gupta P., Cooper J., and Sands M.S. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiology of Disease 16 2 (2004) 360-369
57. Griffey M. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Molecular Therapy 13 3 (2005) 538-547
58. Griffey M., Macauley S.L., Ogilvie J.M., and Sands M.S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Molecular Therapy: the Journal of the American Society of Gene Therapy 12 3 (2005) 413-421
59. Haskell R.E., Hughes S.M., Chiorini J.A., Alisky J.M., and Davidson B.L. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Therapy 10 1 (2003) 34-42
60. Sondhi D., Peterson D.A., Giannaris E.L., Sanders C.T., Mendez B.S., De B., Rostkowski A.B., Blanchard B., Bjugstad K., Sladek Jr. J.R., Redmond Jr. D.E., Leopold P.L., Kaminsky S.M., Hackett N.R., and Crystal R.G. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Therapy 12 22 (2005) 1618-1632
61. Passini. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. The Journal of Neuroscience 26 5 (2006) 1334-1342
62. Milto, Nathan's Battle (online) www.nathansbattle.com.
63. Sakurai K., Iizuka S., Shen J.S., Meng X.L., Mori T., Umezawa A., Ohashi T., and Eto Y. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Gene Therapy 11 19 (2004) 1475-1481